Study helps resolve debate about how tumors spread

November 29, 2012
This is a cluster of malignant breast cancer cells (stained brown) metastasized to the liver. Credit: National Cancer Institute

A team of scientists, led by researchers at the University of California, San Diego School of Medicine, has shown for the first time how cancer cells control the ON/OFF switch of a program used by developing embryos to effectively metastasize in vivo, breaking free and spreading to other parts of the body, where they can proliferate and grow into secondary tumors.

The findings are published in the December 11 issue of the journal Cancer Cell.

In 90 percent of cancer deaths, it is the spreading of cancer, known as , which ultimately kills the patient by impacting ever-more tissues and functions until the body fails. Ten years ago, a French cancer researcher named Jean Paul Thiery hypothesized that metastasized by exploiting a developmental process known as epithelial-to-mesenchymal transition or EMT.

EMT is seen in developing whose cells transform from stationary epithelial cells into more mobile , the latter able to migrate to new locations and create new types of tissue and organs. Thiery proposed that cancer cells also switch "ON" EMT, temporarily changing attributes so that they can detach from primary tumors, enter the bloodstream and seed new tumors elsewhere. After arriving at a new location, the then turn "OFF" the EMT program and grow into carcinoma or tumors.

Thiery's hypothesis was controversial because researchers haven't been able to find supporting evidential proof in vivo. "Although this model was proposed in 2002, there have been no experiments done to attest to it in a spontaneous tumor model," said Jing Yang, PhD, associate professor of pharmacology and pediatrics and senior author of the Cancer Cell paper. "Our new study provides an in vivo demonstration of the reversible EMT in metastasis and helps to resolve the controversy on this leading theory in metastasis."

Using a mouse model, Jeff Tsai, PhD, a in Yang's lab and first author of the study, with help from collaborators at the Whitehead Institute for Biomedical Research in Cambridge, MA and The Sanford-Burnham Medical Research Institute in La Jolla, showed that activation of an EMT-inducing gene called Twist1 is sufficient to turn "ON" the EMT switch and promote carcinoma cells to disseminate into blood circulation. Equally importantly, the researchers found that turning "OFF" the EMT switch at distant sites is essential for disseminated tumor cells to proliferate and form metastases. Their findings indicate that reversible EMT likely represents a key driving force in human carcinoma metastasis.

"There are many similarities between developmental EMT and EMT in metastasis," Yang said. "Both processes seem to use the same cellular machineries and signaling pathways to activate the EMT program. During embryogenesis, the EMT program tends to be more permanent and commit to a mesenchymal fate. Our study shows that carcinoma cells need a reversible EMT to achieve efficient metastasis. It suggests that EMT reversion could be a critical step to wake up tumor cells from dormancy, a phenomenon in which cancer patients develop metastasis years after the initial primary tumor diagnosis and removal."

It's not entirely known how Twist1 becomes active in primary tumors, though previous studies have pointed to factors like hypoxia and inflammation in the tumor microenvironment. Researchers do not know exactly how Twist1 is "turned off at distant organs." Yang said these are subjects of current experiments.

More broadly, the published findings suggest that more research is needed to determine how to target EMT to combat cancer metastasis. Several pharmaceuticals and research institutes are already pursuing EMT inhibitors as possible treatments.

"Since reversion of EMT promotes colonization and growth of metastases, this study actually cautions that therapies inhibiting EMT could be counterproductive in preventing distant metastases when patients already present circulating tumor cells. Instead, blocking EMT reversion may prevent dormant tumor cells from establishing metastases."

Explore further: Study finds switch that lets early lung cancer grow unchecked

Related Stories

Study finds switch that lets early lung cancer grow unchecked

July 11, 2012
Cellular change thought to happen only in late-stage cancers to help tumors spread also occurs in early-stage lung cancer as a way to bypass growth controls, say researchers at Mayo Clinic in Florida. The finding, reported ...

Metastasis of pancreatic cancer in action

January 19, 2012
Ben Stanger, MD, PhD, assistant professor of Medicine in the Division of Gastroenterology at the Perelman School of Medicine, University of Pennsylvania, and Andrew Rhim, MD, a Gastroenterology Fellow in the Stanger lab, ...

New study shows promise for developing new treatments for breast cancer

March 14, 2012
A new study by University of Kentucky researchers provides insight into developing new treatment strategies for basal-like breast cancer, commonly known as triple-negative breast cancer. This cancer is associated with early ...

Signaling pathways point to vulnerability in breast cancer stem cells

June 9, 2011
Whitehead Institute researchers have identified signals from breast epithelial cells that can induce those cells to transition to and maintain a mesenchymal and stem cell-like cell state that imbues both normal and cancer ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.